Skip to main content

Yubin Kang

Professor of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
Box 3961 Med Ctr, Durham, NC 27710
Hematologic Malignancies, Box 3961, Durham, NC 27710

Selected Publications


Chromatin Remodeling in Patient-Derived Colorectal Cancer Models.

Conference Adv Sci (Weinh) · February 21, 2024 Patient-Derived Organoids (PDO) and Xenografts (PDX) are the current gold standards for patient-derived models of cancer (PDMC). Nevertheless, how patient tumor cells evolve in these models and the impact on drug response remains unclear. Herein, the trans ... Full text Link to item Cite

Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · January 2024 The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of respo ... Full text Link to item Cite

Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · December 2023 The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several new options. These include new combinations with second generation proteasome inhibitors (PI); second generation immunomodulators, monoclonal antibodies, CAR T cells, ... Full text Link to item Cite

SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments.

Journal Article Curr Oncol · August 27, 2023 Multiple myeloma (MM) is a common hematological malignancy that has fostered several new therapeutic approaches to combat newly diagnosed or relapsed MM. While the field has advanced over the past 2 decades, the majority of patients will develop resistance ... Full text Open Access Link to item Cite

RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect.

Journal Article Cells · August 3, 2023 Retinoid X receptor (RXR) heterodimerizes with the PPAR nuclear hormone receptor and regulates its downstream events. We investigated the effects of RXR agonists (LG100754, bexarotene, AGN194204, and LG101506) on lenalidomide's anti-myeloma activity, T cel ... Full text Link to item Cite

Inhibition of Sphingosine Kinase 2 Results in PARK2-Mediated Mitophagy and Induces Apoptosis in Multiple Myeloma.

Journal Article Curr Oncol · March 4, 2023 Mitophagy plays an important role in maintaining mitochondrial homeostasis by clearing damaged mitochondria. Sphingosine kinase 2 (SK2), a type of sphingosine kinase, is an important metabolic enzyme involved in generating sphingosine-1-phosphate. Its expr ... Full text Open Access Link to item Cite

A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.

Journal Article Transplant Cell Ther · March 2023 Despite the exciting advancement of novel therapies, chronic graft-versus-host disease (cGVHD) remains the most common cause of non-relapse mortality after allogeneic hematopoietic stem cell transplantation (HCT). Frontline treatment of cGVHD involves syst ... Full text Link to item Cite

Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma.

Journal Article Ann Hematol · February 2023 Multiple myeloma (MM) remains an incurable disease and there is an unmet medical need for novel therapeutic drugs that do not share similar mechanisms of action with currently available agents. Sphingosine kinase 2 (SK2) is an innovative molecular target f ... Full text Link to item Cite

Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · January 2023 Primary systemic light chain amyloidosis (SLCA) is characterized by production of light chains that get converted to amyloid fibrils with an affinity for visceral organs and causing organ dysfunction. The therapy for SLCA is directed to recovering the func ... Full text Link to item Cite

Thioredoxin-1 regulates self-renewal and differentiation of murine hematopoietic stem cells through p53 tumor suppressor.

Journal Article Exp Hematol Oncol · October 31, 2022 BACKGROUND: Thioredoxin-1 (TXN1) is one of the major cellular antioxidants in mammals and is involved in a wide range of physiological cellular responses. However, little is known about the roles and the underlying molecular mechanisms of TXN1 in the regul ... Full text Link to item Cite

Mechanistic Studies and a Retrospective Cohort Study: The Interaction between PPAR Agonists and Immunomodulatory Agents in Multiple Myeloma.

Journal Article Cancers (Basel) · October 27, 2022 Our previous study demonstrated that peroxisome proliferator-activated receptor (PPAR) agonists downregulated cereblon (CRBN) expression and reduced the anti-myeloma activity of lenalidomide in vitro and in vivo. We aimed to determine whether DNA methylati ... Full text Link to item Cite

PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo.

Journal Article Cancer Lett · October 1, 2022 Many patients with multiple myeloma (MM) have comorbidities and are treated with PPAR agonists. Immunomodulatory agents (IMiDs) are the cornerstones for MM therapy. Currently, little is known about how co-administration of PPAR agonists impacts lenalidomid ... Full text Link to item Cite

Emerging Evidence of the Significance of Thioredoxin-1 in Hematopoietic Stem Cell Aging.

Journal Article Antioxidants (Basel) · June 29, 2022 The United States is undergoing a demographic shift towards an older population with profound economic, social, and healthcare implications. The number of Americans aged 65 and older will reach 80 million by 2040. The shift will be even more dramatic in th ... Full text Link to item Cite

Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.

Journal Article Clin Lymphoma Myeloma Leuk · May 2022 BACKGROUND: In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) therapy, showed encouraging efficacy in US patients with multiple myeloma (MM) wh ... Full text Link to item Cite

Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.

Journal Article Pharmacol Ther · April 2022 Although treatment outcomes of multiple myeloma patients have improved significantly during the last two decades, myeloma is still an incurable disease. There are newly emerging immunotherapies to treat multiple myeloma including monoclonal antibodies, ant ... Full text Link to item Cite

Chromatin Remodeling in Patient-Derived Colorectal Cancer Models.

Conference Adv Sci (Weinh) · February 21, 2024 Patient-Derived Organoids (PDO) and Xenografts (PDX) are the current gold standards for patient-derived models of cancer (PDMC). Nevertheless, how patient tumor cells evolve in these models and the impact on drug response remains unclear. Herein, the trans ... Full text Link to item Cite

Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · January 2024 The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of respo ... Full text Link to item Cite

Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · December 2023 The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several new options. These include new combinations with second generation proteasome inhibitors (PI); second generation immunomodulators, monoclonal antibodies, CAR T cells, ... Full text Link to item Cite

SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments.

Journal Article Curr Oncol · August 27, 2023 Multiple myeloma (MM) is a common hematological malignancy that has fostered several new therapeutic approaches to combat newly diagnosed or relapsed MM. While the field has advanced over the past 2 decades, the majority of patients will develop resistance ... Full text Open Access Link to item Cite

RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect.

Journal Article Cells · August 3, 2023 Retinoid X receptor (RXR) heterodimerizes with the PPAR nuclear hormone receptor and regulates its downstream events. We investigated the effects of RXR agonists (LG100754, bexarotene, AGN194204, and LG101506) on lenalidomide's anti-myeloma activity, T cel ... Full text Link to item Cite

Inhibition of Sphingosine Kinase 2 Results in PARK2-Mediated Mitophagy and Induces Apoptosis in Multiple Myeloma.

Journal Article Curr Oncol · March 4, 2023 Mitophagy plays an important role in maintaining mitochondrial homeostasis by clearing damaged mitochondria. Sphingosine kinase 2 (SK2), a type of sphingosine kinase, is an important metabolic enzyme involved in generating sphingosine-1-phosphate. Its expr ... Full text Open Access Link to item Cite

A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.

Journal Article Transplant Cell Ther · March 2023 Despite the exciting advancement of novel therapies, chronic graft-versus-host disease (cGVHD) remains the most common cause of non-relapse mortality after allogeneic hematopoietic stem cell transplantation (HCT). Frontline treatment of cGVHD involves syst ... Full text Link to item Cite

Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma.

Journal Article Ann Hematol · February 2023 Multiple myeloma (MM) remains an incurable disease and there is an unmet medical need for novel therapeutic drugs that do not share similar mechanisms of action with currently available agents. Sphingosine kinase 2 (SK2) is an innovative molecular target f ... Full text Link to item Cite

Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · January 2023 Primary systemic light chain amyloidosis (SLCA) is characterized by production of light chains that get converted to amyloid fibrils with an affinity for visceral organs and causing organ dysfunction. The therapy for SLCA is directed to recovering the func ... Full text Link to item Cite

Thioredoxin-1 regulates self-renewal and differentiation of murine hematopoietic stem cells through p53 tumor suppressor.

Journal Article Exp Hematol Oncol · October 31, 2022 BACKGROUND: Thioredoxin-1 (TXN1) is one of the major cellular antioxidants in mammals and is involved in a wide range of physiological cellular responses. However, little is known about the roles and the underlying molecular mechanisms of TXN1 in the regul ... Full text Link to item Cite

Mechanistic Studies and a Retrospective Cohort Study: The Interaction between PPAR Agonists and Immunomodulatory Agents in Multiple Myeloma.

Journal Article Cancers (Basel) · October 27, 2022 Our previous study demonstrated that peroxisome proliferator-activated receptor (PPAR) agonists downregulated cereblon (CRBN) expression and reduced the anti-myeloma activity of lenalidomide in vitro and in vivo. We aimed to determine whether DNA methylati ... Full text Link to item Cite

PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo.

Journal Article Cancer Lett · October 1, 2022 Many patients with multiple myeloma (MM) have comorbidities and are treated with PPAR agonists. Immunomodulatory agents (IMiDs) are the cornerstones for MM therapy. Currently, little is known about how co-administration of PPAR agonists impacts lenalidomid ... Full text Link to item Cite

Emerging Evidence of the Significance of Thioredoxin-1 in Hematopoietic Stem Cell Aging.

Journal Article Antioxidants (Basel) · June 29, 2022 The United States is undergoing a demographic shift towards an older population with profound economic, social, and healthcare implications. The number of Americans aged 65 and older will reach 80 million by 2040. The shift will be even more dramatic in th ... Full text Link to item Cite

Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.

Journal Article Clin Lymphoma Myeloma Leuk · May 2022 BACKGROUND: In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) therapy, showed encouraging efficacy in US patients with multiple myeloma (MM) wh ... Full text Link to item Cite

Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.

Journal Article Pharmacol Ther · April 2022 Although treatment outcomes of multiple myeloma patients have improved significantly during the last two decades, myeloma is still an incurable disease. There are newly emerging immunotherapies to treat multiple myeloma including monoclonal antibodies, ant ... Full text Link to item Cite

Anaplastic Multiple Myeloma: Case Series and Literature Review.

Journal Article Asploro journal of biomedical and clinical case reports · January 2022 BackgroundAnaplastic multiple myeloma (AMM) is a very rare but distinct subtype of multiple myeloma (MM) with an extremely poor prognosis. Due to its rarity, AMM lacks detailed descriptions and clear definitions. Moreover, there is no consensus on ... Full text Cite

NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.

Journal Article J Natl Compr Canc Netw · January 2022 The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma. These NCCN Guidelines Insights highlight ... Full text Link to item Cite

An autologous humanized patient-derived xenograft (PDX) model for evaluation of nivolumab immunotherapy in renal cell cancer: a case report.

Journal Article Stem cell investigation · January 2022 BackgroundThere is an unmet need for developing faithful animal models for preclinical evaluation of immunotherapy. The current approach to generate preclinical models for immunotherapy evaluation has been to transplant CD34+ cells from ... Full text Cite

Efficacy of Treatments for Patients with Triple-Class Refractory (TCR) Multiple Myeloma (MM): Benchmark for New Agents Utilizing Real-World Data (RWD)

Conference Blood · November 5, 2021 AbstractBackground: MM that is refractory to a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 monoclonal antibody (CD38MoAb) is labeled triple-class refractory (TCR) and recogni ... Full text Cite

PIM Kinases in Multiple Myeloma.

Journal Article Cancers (Basel) · August 26, 2021 Multiple myeloma (MM) remains an incurable disease and novel therapeutic agents/approaches are urgently needed. The PIM (Proviral insertion in murine malignancies) serine/threonine kinases have 3 isoforms: PIM1, PIM2, and PIM3. PIM kinases are engaged with ... Full text Link to item Cite

Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma.

Conference Journal of Clinical Oncology · May 20, 2021 8030 Background: CARTITUDE-1 is a single arm study of Ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) anti-BCMA CAR-T cell therapy in US patients (pts) with relapsed multiple myeloma (RRMM) refractory to both IMiD and proteas ... Full text Cite

Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation.

Journal Article Bone Marrow Transplant · January 2021 Prophylactic donor lymphocyte infusions (DLI) are used to augment post-transplant immune recovery to reduce both infectious complications and disease recurrence. Preclinical studies implicate the naive T-cell subset as the primary driver of graft-versus-ho ... Full text Link to item Cite

Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · December 2, 2020 Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, and newly ... Full text Link to item Cite

Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma.

Journal Article JCO Oncol Pract · August 2020 PURPOSE: We performed a retrospective chart review on 393 patients with multiple myeloma (MM) to determine the utility of the gamma gap (GG). METHODS: We calculated the difference between a patient's total serum protein and albumin as a point-of-care test ... Full text Link to item Cite

The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.

Journal Article Cancer Med · August 2020 We determined the impact of bone marrow fibrosis (BMF) on the clinical outcomes of newly diagnosed multiple myeloma (NDMM) patients in the current era of myeloma therapy. A total of 393 MM patients were included in the final analysis. The median followup w ... Full text Link to item Cite

A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.

Journal Article J Clin Invest · May 1, 2020 An in-depth understanding of immune escape mechanisms in cancer is likely to lead to innovative advances in immunotherapeutic strategies. However, much remains unknown regarding these mechanisms and how they impact immunotherapy resistance. Using several p ... Full text Link to item Cite

Intravital imaging of mouse embryos.

Journal Article Science · April 10, 2020 Embryonic development is a complex process that is unamenable to direct observation. In this study, we implanted a window to the mouse uterus to visualize the developing embryo from embryonic day 9.5 to birth. This removable intravital window allowed manip ... Full text Open Access Link to item Cite

PINK1-Dependent Mitophagy Regulates the Migration and Homing of Multiple Myeloma Cells via the MOB1B-Mediated Hippo-YAP/TAZ Pathway.

Journal Article Adv Sci (Weinh) · March 2020 The roles of mitochondrial dysfunction in carcinogenesis remain largely unknown. The effects of PTEN-induced putative kinase 1 (PINK1)-dependent mitophagy on the pathogenesis of multiple myeloma (MM) are determined. The levels of the PINK1-dependent mitoph ... Full text Link to item Cite

The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.

Journal Article Cell Immunol · November 2019 A cure for multiple myeloma (MM), a malignancy of plasma cells, remains elusive. Nearly all myeloma patients will eventually relapse and develop resistance to currently available treatments. There is an unmet medical need to develop novel and effective the ... Full text Link to item Cite

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.

Journal Article J Natl Compr Canc Netw · October 1, 2019 The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma ... Full text Link to item Cite

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Journal Article Leukemia · September 2019 The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab and isatuximab, has significantly impacted the management of patients with multiple myeloma (MM). Outcomes of patients with MM refractory to CD38 MoABs have not been describ ... Full text Link to item Cite

Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.

Journal Article Cancer Lett · January 2019 Multiple myeloma remains an incurable disease, and continued efforts are required to develop novel agents and novel drug combinations with more effective anti-myeloma activity. Here, we show that the pan-PIM kinase inhibitors SGI1776 and CX6258 exhibit sig ... Full text Link to item Cite

Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myeloma.

Journal Article J Cancer Metastasis Treat · 2019 Metabolism is defined as the collection of complex biochemical processes that living cells use to generate energy and maintain their growth and survival. Metabolism encompasses the synthesis and breakdown of glucose, fatty acids, and amino acids; the gener ... Full text Link to item Cite

The challenges of checkpoint inhibition in the treatment of multiple myeloma.

Journal Article Cell Immunol · December 2018 Despite significant improvements in the overall survival of patients with multiple myeloma (MM) over the past 15 years, the disease remains incurable. Treatment options are limited for patients who have relapsed or are refractory to immunomodulatory drugs ... Full text Link to item Cite

The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation.

Journal Article Cancer Med · July 2018 Multiple myeloma (MM) remains an incurable disease in need of the development of novel therapeutic agents and drug combinations. ABT-199 is a specific Bcl-2 inhibitor in clinical trials for MM; however, its activity as a single agent was limited to myeloma ... Full text Link to item Cite

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.

Journal Article J Hematol Oncol · February 27, 2018 BACKGROUND: Although current chemotherapy using bortezomib (Velcade) against multiple myeloma in adults has achieved significant responses and even remission, a majority of patients will develop acquired resistance to bortezomib. Increased thioredoxin leve ... Full text Link to item Cite

High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Journal Article Bone Marrow Transplant · January 2018 Single-agent high-dose melphalan (HDM, 200 mg/m2) has been the most commonly used conditioning regimen prior to autologous stem cell transplant, since its introduction in 1992. We used a more aggressive alkylator-based conditioning regimen in an attempt to ... Full text Link to item Cite

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

Journal Article J Natl Compr Canc Netw · January 2018 The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, evaluation, treatment, including supportive-care, and follow-up for patients with myeloma. These NCCN Guidelines Insights highlight the important updates/changes specific to th ... Full text Link to item Cite

Thioredoxin mitigates radiation-induced hematopoietic stem cell injury in mice.

Journal Article Stem Cell Res Ther · November 15, 2017 BACKGROUND: Radiation exposure poses a significant threat to public health. Hematopoietic injury is one of the major manifestations of acute radiation sickness. Protection and/or mitigation of hematopoietic stem cells (HSCs) from radiation injury is an imp ... Full text Link to item Cite

Phase I/II dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (BPd) in patients with relapsed/refractory multiple myeloma.

Conference Journal of Clinical Oncology · May 20, 2017 8008 Background: The combination of bendamustine, pomalidomide, and dexamethasone (BPd) displays promising activity in heavily pretreated RRMM. In the Phase I portion, MTD was 120 mg/m2bendamustine/3mg pomali ... Full text Cite

Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.

Journal Article J Geriatr Oncol · May 2017 OBJECTIVES: Multiple myeloma (MM) primarily strikes older adults, but full-dose chemotherapy such as bortezomib (Velcade), cyclophosphamide and dexamethasone (VCD) is often excessively toxic to very old or frail adults and those with substantial comorbidit ... Full text Link to item Cite

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.

Journal Article Biol Blood Marrow Transplant · February 2017 Comprehensive recommendations for maintenance therapy after autologous stem cell transplantation (ASCT) for patients with multiple myeloma (MM) have yet to be defined. Bortezomib has been utilized as maintenance therapy after ASCT, but data attesting to th ... Full text Link to item Cite

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.

Journal Article J Hematol Oncol · August 17, 2016 BACKGROUND: The binding of CXCR4 with its ligand (stromal-derived factor-1) maintains hematopoietic stem/progenitor cells (HSPCs) in a quiescent state. We hypothesized that blocking CXCR4/SDF-1 interaction after hematopoietic stem cell transplantation (HSC ... Full text Open Access Link to item Cite

Pim1 kinase regulates c-Kit gene translation.

Journal Article Exp Hematol Oncol · 2016 BACKGROUND: Receptor tyrosine kinase, c-Kit (CD117) plays a pivotal role in the maintenance and expansion of hematopoietic stem/progenitor cells (HSPCs). Additionally, over-expression and/or mutational activation of c-Kit have been implicated in numerous m ... Full text Link to item Cite

A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

Conference Blood · December 3, 2015 AbstractBackgroundBendamustine, a bifunctional mechlorethamine derivative with alkylating properties and pomalidomide, an IMiD® immunomodulatory agent, have both demonstrated ... Full text Cite

Similar dynamics of intraapheresis autologous 34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor

Journal Article Transfusion · December 2014 BackgroundCompared with growth factor (G) alone, the combination of G with plerixafor ( Full text Cite

Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.

Journal Article Blood · September 18, 2014 Sphingolipid metabolism is being increasingly recognized as a key pathway in regulating cancer cell survival and proliferation. However, very little is known about its role in multiple myeloma (MM). We investigated the potential of targeting sphingosine ki ... Full text Link to item Cite

Thioredoxin and hematologic malignancies.

Journal Article Adv Cancer Res · 2014 Thioredoxin (Trx) is an inflammation-inducible small oxidoreductase protein ubiquitously expressed in all organisms. Trx acts both intracellularly and extracellularly and is involved in a wide range of physiological cellular responses. Inside the cell, Trx ... Full text Link to item Cite

Senile transthyretin cardiac amyloidosis in patients with plasma cell dyscrasias: importance of cardiac biopsy for making the correct diagnosis.

Journal Article Aperito J Cell Mol Biol · 2014 Amyloidosis refers to a group of widely diverse conditions characterized by the deposition of insoluble protein within the extracellular space, leading to disruption of normal organ function. AL primary amyloidosis is associated with plasma cell dyscrasias ... Link to item Cite

Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice

Journal Article Journal of Hematology & Oncology · December 2013 AbstractBackgroundPim (p roviral i nsertion in m uri ... Full text Cite

Fact or fiction - identifying the elusive multiple myeloma stem cell

Journal Article Journal of Hematology & Oncology · December 2013 Full text Cite

Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms

Journal Article Biomarker Research · December 2013 AbstractHighly active antiretroviral therapy (HAART) has significantly improved the outcome and survival of human immunodeficiency virus (HIV)-infected patients. Subsequently, long-term morbidities including cancer have bec ... Full text Cite

Pim1 Serine/Threonine Kinase Regulates the Number and Functions of Murine Hematopoietic Stem Cells

Journal Article Stem Cells · June 1, 2013 AbstractThe genes and pathways that govern the functions and expansion of hematopoietic stem cells (HSC) are not completely understood. In this study, we investigated the roles of serine/threonine Pim kinase ... Full text Cite

Insulin-like growth factor 1 mitigates hematopoietic toxicity after lethal total body irradiation.

Journal Article Int J Radiat Oncol Biol Phys · March 15, 2013 PURPOSE: To investigate whether and how insulin-like growth factor 1 (IGF-1) mitigates hematopoietic toxicity after total body irradiation. METHODS AND MATERIALS: BALB/c mice were irradiated with a lethal dose of radiation (7.5 Gy) and treated with IGF-1 a ... Full text Link to item Cite

Insulin-Like Growth Factor 1 Mitigates Hematopoietic Toxicity After Lethal Total Body Irradiation

Conference Biology of Blood and Marrow Transplantation · February 2013 Full text Cite

Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy

Journal Article Experimental Hematology & Oncology · December 2012 Full text Cite

Pegfilgrastim‐ versus filgrastim‐based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis

Journal Article Transfusion · November 2012 BACKGROUND: Plerixafor enhances the ability of filgrastim (FIL) to mobilize CD34+ cells but adds cost to the mobilization. We hypothesized that replacing weight‐based FIL with flat‐dose pegfilgrastim (PEG) in a validated cost ... Full text Cite

Strategies to enhance hematopoietic stem cell engraftment following transplantation

Chapter · February 15, 2012 This book provides concise reviews of novel developments, as well as possible future developments on CXCR4. ... Cite

Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model.

Journal Article PLoS One · June 28, 2010 The interaction between stromal cell-derived factor-1 (SDF-1) with CXCR4 chemokine receptors plays an important role in hematopoiesis following hematopoietic stem cell transplantation. We examined the efficacy of post transplant administration of a specifi ... Full text Open Access Link to item Cite

Immune reconstitution

Chapter · 2010 Cite

Unmanipulated or CD34 selected haplotype mismatched transplants.

Journal Article Curr Opin Hematol · November 2008 PURPOSE OF REVIEW: Unmanipulated or CD34 selected haplotype mismatched transplantation provides the benefits of hematopoietic stem cell transplant for nearly all patients who do not have a human leukocyte antigen fully matched sibling or who urgently need ... Full text Link to item Cite

Integration Site Choice of a Feline Immunodeficiency Virus Vector

Journal Article Journal of Virology · September 2006 ABSTRACTWe mapped 226 unique integration sites in human hepatoma cells following gene transfer with a feline immunodeficiency virus (FIV)-based lentivirus vector. FIV integrated across the entire length of the tr ... Full text Cite

Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer

Journal Article Blood · September 1, 2005 AbstractHemophilia A is a clinically important coagulation disorder caused by the lack or abnormality of plasma coagulation factor VIII (FVIII). Gene transfer of the FVIII cDNA to hepatocytes using lentivira ... Full text Cite

CCL20 Is an Inducible Product of Human Airway Epithelia with Innate Immune Properties

Journal Article American Journal of Respiratory Cell and Molecular Biology · November 2003 Full text Cite

In Vivo Gene Transfer Using a Nonprimate Lentiviral Vector Pseudotyped with Ross River Virus Glycoproteins

Journal Article Journal of Virology · September 15, 2002 ABSTRACT Vectors derived from lentiviruses provide a promising gene delivery system. We examined the in vivo gene transfer efficiency and tissue or cell tropism of a feline immunodeficiency virus (FIV ... Full text Cite

Mechanisms of tolerance induction by an Ig-peptide molecule expressed and secreted by B cells

Journal Article Journal of immunology (Baltimore, Md. : 1950) · 2000 Cite

Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: The IgG scaffold is important for induction and maintenance of immune hyporesponsiveness

Journal Article Proceedings of the National Academy of Sciences · July 20, 1999 IgG molecules can be highly tolerogenic carriers for associated antigens. Previously, we reported that recipients of bone marrow or lipopolysaccharide-stimulated B-cell blasts, both of which were retrovirally gene-transferred with an immunodominant ... Full text Cite

Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis.

Journal Article Biochem Pharmacol · May 17, 1996 The glyoxalase I inhibitor diester, S-p-bromobenzyl-glutathione cyclopentyl diester (BrBzGSHCp2), inhibited the growth of human leukaemia 60 (HL60) cells in vitro. The median growth inhibitory concentration GC50 value of BrBzGSHCp2 was 4.23 +/- 0.001 micro ... Full text Link to item Cite

Interleukin-4

Chapter · 1996 Cite

Tumor Cell Surface Markers and Differentiation on Multiple Myeloma

Journal Article Chinese Journal of Hematology · 1992 Cite

Hypertension Associated with Cyclosporine A Treatment in Bone Marrow Transplantation

Journal Article Foreign Medicine (Blood Transfusion & Hematology) · 1991 Cite

Therapeutic Progress in Multiple Myeloma

Journal Article Foreign Medicine (Blood Transfusion & Hematology) · 1990 Cite